Year-two follow-up results of an observational study conducted in Crohn's disease and ulcerative colitis patients treated with infliximab biosimilar CT-P13 in a real-life setting

被引：0
|
作者：
Laharie, D. [1 ]
Pierron, G. [2 ]
Brault, Y. [3 ]
Bouhnik, Y. [4 ]
Nancey, S. [5 ,6 ]
机构：
[1] Univ Hosp Ctr Bordeaux, Dept Gastroenterol, Bordeaux, France
[2] Pfizer, Inflammat & Immunol, Paris, France
[3] Pfizer, Stat, Paris, France
[4] Paris IBD Ctr, Grp Hosp Prive Ambroise Pare Hartmann, Neuilly Sur Seine, France
[5] Lyon South Hosp Pierre Benite, Lyon, France
[6] INSERM, U1111 CIRI, Dept Gastroenterol, Lyon, France
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P529
引用
收藏
页码：658 / 659
页数：2
相关论文
共 50 条
  • [41] Effectiveness and Safety of CT-P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis
    Codreanu, Catalin
    Sirova, Klara
    Jarosova, Katerina
    Batalov, Anastas
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [42] Anti-TNF α antibodies in patients with inflammatory bowel disease naive to anti-TNF therapy treated with biosimilar infliximab (CT-P13): a prospective single-centre real-life study
    Filip, R.
    Pekala, A.
    Jarmakiewicz-Czaja, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S396 - S397
  • [43] BIOSIMILAR INFLIXIMAB THERAPY IN RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS:A LONG-TERM FOLLOW-UP STUDY ON INFLIXIMAB-NAIVE PATIENTS AND PATIENTS SWITCHED FROM THE ORIGINATORTO THE BIOSIMILAR CT-P13
    Fautrel, B.
    Assing, M.
    Mammar, N.
    Marotte, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 529 - 530
  • [44] Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13
    Marotte, Hubert
    Assing, Maryse
    Mammar, Nadir
    Brault, Yves
    Fautrel, Bruno
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1683 - 1685
  • [45] Comparison of the pharmacokinetics of CT-P13 between Crohn's Disease and Ulcerative Colitis in biologic-naive patients; a prospective multi-center observational study of the KASID
    Kim, E. S.
    Park, D. I.
    Kim, H. J.
    Lee, Y. J.
    Koo, J. S.
    Kim, E. S.
    Yoon, H.
    Lee, J. H.
    Kim, J. W.
    Shin, S. J.
    Kim, H. W.
    Kim, H. S.
    Park, Y. S.
    Kim, Y. S.
    Kim, T. O.
    Lee, J.
    Choi, C. H.
    Han, D. S.
    Chun, J.
    Kim, H. S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S101 - S102
  • [46] A NOVEL SUBCUTANEOUS INFLIXIMAB (CT-P13) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: WEEK54 AND SWITCHING RESULTS FROM A MULTICENTER, RANDOMISED CONTROLLED PIVOTAL TRIAL
    Reinisch, Walter
    Leszczyszyn, Jaroslaw
    Dudkowiak, Robert
    Lahat, Adi
    Gawdis-Wojnarska, Beata
    Pukitis, Aldis
    Horynski, Marek
    Farkas, Katalin
    Kierkus, Jaroslaw
    Kowalski, Maciej
    Schreiber, Stefan
    Ben-Horin, Shomron
    Lee, Sang Joon
    Kim, Sung Hyun
    Kim, Han Na
    Kim, Mi Rim
    Kim, Yun Ah
    Ye, Byong Duk
    GASTROENTEROLOGY, 2020, 158 (06) : S193 - S193
  • [47] Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study
    Garcia-Bosch, Orlando
    Aceituno, Montserrat
    Ordas, Ingrid
    Etchevers, Josefina
    Sans, Miquel
    Feu, Faust
    Panes, Julian
    Ricart, Elena
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (07) : 2051 - 2059
  • [48] Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results
    Kim, Y. H.
    Ye, B. D.
    Pesegova, M.
    Alexeeva, O.
    Osipenko, M.
    Lahat, A.
    Dorofeyev, A.
    Salamon, A.
    Fishman, S.
    Levchenko, O.
    Cheon, J. H.
    Scribano, M. L.
    Mateescu, R. -B.
    Lee, K. M.
    Eun, C. S.
    Lee, S. J.
    Lee, S. Y.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S62 - S62
  • [49] Pharmacokinetic behavior and clinical outcomes following a switch from originator to biosimilar CT-P13 infliximab in inflammatory bowel disease: 8 months of real-life experience
    Sanchez-Hernandez, J. G.
    Martin-Gutierrez, N.
    Fernandez-Caballero, R.
    Rebollo-Diaz, N.
    Munoz, F.
    Pordomingo, A. F.
    Saez-Fernandez, E. M.
    Otero-Lopez, M. J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 366 - 366
  • [50] PHASE III RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL TO COMPARE BIOSIMILAR INFLIXIMAB (CT-P13) WITH INNOVATOR INFLIXIMAB (INX) IN PATIENTS WITH ACTIVE CROHN'S DISEASE: EARLY EFFICACY AND SAFETY RESULTS
    Kim, Young Ho
    Ye, Byong Duk
    Pesegova, Marina
    Alexeeva, Olga
    Osipenko, Marina
    Lahat, Adi
    Dorofeyev, Andrey
    Salamon, Agnes
    Fishman, Sigal
    Levchenko, Olena
    Cheon, Jae Hee
    Scribano, Maria L.
    Mateescu, Radu-Bogdan
    Lee, Kang-Moon
    Eun, Chang Soo
    Lee, Sang Joon
    Lee, Sung Young
    GASTROENTEROLOGY, 2017, 152 (05) : S65 - S65
12345